We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » MHRA Presents Business Plan as Part of Five-Year Strategy

MHRA Presents Business Plan as Part of Five-Year Strategy

July 2, 2015

Ensuring efficient implementation of EU device regulations is a key activity the UK’s Medicines and Healthcare products Regulatory Agency has tasked for itself over the next year, according to a new business plan.

The plan is part of a five-year strategy to promote effective regulation for devices and drugs and further develop the National Institute for Biological Standards and Control and the Clinical Practice Research Datalink.

Specific device-related goals in the 2015-16 plan include collaborating with international agencies, such as the International Medical Device Regulators Forum, to harmonize global regulatory standards. Part of this goal is clarifying the European position on implementing elements of IMDRF’s medical device single audit program by the end of the third quarter. Implementing the MDSAP program in the EU has proven challenging because every participant must have confidentiality agreements with every other player. Agreements for each of the 28 nations would need to be negotiated individually.

The plan is part of thee MHRA’s plan to revise its medical device funding model. According to the business plan, funding for device regulation is half the level it was in 2003 in real terms. That comes even as adverse event reporting has increased more than 50 percent since 2009. Over the next year, the plan calls for about U.S. $14.3 million in funding and investment in efficiencies from the Department of Health.

To read the full report, visit www.fdanews.com/07-06-15-mhrabusinessplan.pdf.
– Elizabeth Hollis

Regulatory Affairs

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing